Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Plus Androgen Suppression Therapy in Metastatic Prostate Cancer
NCT01498978Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Feb 2012
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Started Feb 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01498978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498978.